Physician profile
Sean E Mccain
NPI 1629050307
$1,302.21
in general payments reported to CMS, 2019-2025
20 companies · $216 in 2025
The $216 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $607 · 2024: $479 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,302.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $370.05 | 2023-2025 | Korlym |
| Abbvie INC. | $255.41 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $163.51 | 2023 | Fasenra, Farxiga |
| Novo Nordisk INC | $82.38 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $70.78 | 2024-2025 | Recorlev |
| Otsuka America Pharmaceutical, INC. | $59.81 | 2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.80 | 2023-2024 | Caplyta |
| Novartis Pharmaceuticals Corporation | $33.62 | 2023-2024 | |
| Lilly USA, LLC | $33.59 | 2023-2024 | Zepbound, Mounjaro |
| Grifols USA, LLC | $21.04 | 2025 | Prolastin-C Liquid |
| Ironshore Pharmaceuticals INC. | $20.28 | 2024 | |
| Axsome Therapeutics, INC. | $19.62 | 2025 | Auvelity |
| Amgen INC. | $17.52 | 2025 | Otezla, Repatha |
| Corium, LLC | $17.17 | 2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $15.95 | 2023 | Spravato |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $15.79 | 2023 | |
| Neurocrine Biosciences, INC. | $15.53 | 2023 | Ingrezza |
| Antares Pharma, INC. | $15.32 | 2025 | Xyosted |
| Abbott Laboratories | $14.43 | 2025 | Freestyle Libre |
| Phathom Pharmaceuticals, INC. | $13.61 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Mccain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.